Regeneron Pharmaceuticals is a leading biotechnology company that focuses on the discovery, development, and commercialization of innovative medicines. The company was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron's product portfolio includes a range of therapies for various diseases, including eye diseases, allergic and inflammatory conditions, and cancer. The company's most successful product is Eylea, a blockbuster drug for wet age-related macular degeneration and diabetic macular edema. Regeneron has a strong commitment to research and development, with a focus on using cutting-edge technologies such as gene editing and artificial intelligence to drive innovation. The company has also been recognized for its corporate social responsibility efforts, including its support for STEM education and its commitment to sustainability.